

In re Application of Danièle Mathieu et al.

Serial No.: 10/587,874

Filed: July 28, 2006

For: ANGIOGENESIS INHIBITORS, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FOR TREATING DISEASES RELATED TO ANGIOGENETIC DEREGULATION

Mail Stop PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment in the above-identified application.

- Small entity status of this application under 37 CFR §1.9 and §1.27 has been established.
- A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.
- No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY	OTHER THAN SMALL ENTITY
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	RATE	RATE
TOTAL	* 19	- **20 =	0	x 50 = \$
INDEP.	* 3	- ** 3 =	0	x 200 = \$
Application Size Fee			\$	x 250 = \$
First Presentation of Multiple Dependent Claim			+ 180 = \$	+ 360 = \$
TOTAL ADDITIONAL FEE			\$ _____	OR \$ _____

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.


The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- Please charge my Deposit Account No. 50-2719 in the amount of \$ _____. A duplicate copy of this sheet is enclosed.
- Payment in the amount of \$ _____ is attached.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-2719. A duplicate copy of this sheet is enclosed.

x Any filing fees under 37 CFR §1.16 for the presentation of extra claims.

x Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.

Respectfully submitted,


T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC:lh
(215)656-3381

IAP13 Rec'd PCT/PTO 16 NOV 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	:	Customer No.: 035811
Examiner	:	
Serial No.	:	10/587,874
Filed	:	July 28, 2006
Inventors	:	Danièle Mathieu Jamal Temsamani Michel Kaczorek
Title	:	ANGIOGENESIS INHIBITORS, COMPOSITIONS CONTAINING SAME AND USE THEREOF FOR TREATING DISEASES RELATED TO ANGIOGENETIC DEREGLULATION
		Docket No.: BDM-06-1215
		Confirmation No.: 2549

Dated: November 16, 2006

MAIL STOP PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

37 CFR 1.10
EXPRESS MAIL CERTIFICATION

“Express Mail” mailing label number: **EV 548526307 US**

Date of Deposit: **November 16, 2006**

DESCRIPTION OF CONTENTS: Postcard, Supplemental Application Data Sheet (1 page), copies of Forms PCT/IB/301 and 304, English translation of PCT Application, including 22 pages of Specification, 6 pages of Claims and 7 sheets of Drawings, with executed Certified Translation of Documents, Amendment Transmittal Letter, in duplicate, Preliminary Amendment, Substitute Specification (Marked-Up), Substitute Specification (Clean Copy), hard copy of Sequence Listing with computer readable form on diskette and Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821 – 1.825, executed Combined Declaration, Power of Attorney and Petition, Information Disclosure Statement and Form PTO-1449 with copies of publications and International Search Report.

I hereby certify that this paper or fee is being deposited with the United States Postal Service “Express Mail Post Office to Addressee” service under 37 CFR 1.10 on the date indicated above and is addressed to **Mail Stop PCT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Leslie Hood

(Typed or printed name of person mailing paper or fee)

Leslie Hood

(Signature of person mailing paper or fee)